614 McKinley Place N.E.
264 articles with Bio-Techne
Bio-Techne Corporation has partnered with Autolomous to implement a first of its kind electronic batch record system, AutoloMATETM, at Bio-Techne's GMP cellular manufacturing center.
Bio-Techne Corporation announced it is joining the Cell and Gene Therapy Catapult process analytical technology consortium, which includes over 20 pharmaceutical companies, technology providers, therapy developers, and charities.
Kantaro's Semi-Quantitative Antibody Test Kit Receives Health Canada Authorization Under the COVID-19 Interim Order
COVID-SeroKlir detects both the presence and precise level of neutralizing IgG antibodies with 98.8% sensitivity and 99.6% specificity
Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:00 p.m. EDT.
Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications
Bio-Techne Corporation (NASDAQ: TECH) today announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on its ProteinSimple branded, multiplexing immunoassay instrument, Ella.
Multisite Study Demonstrates Utility of Asuragen Kit for Identifying Variants Linked to Spinal Muscular Atrophy
One kit provides comprehensive, reproducible detection of variants for diagnostics and carrier screening using a simple workflow that produces results in less than four hours
The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States.
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2021.
Bio-Techne Corporation and 908 Devices announced a joint collaboration to develop an extended workflow solution for protein characterization.
908 Devices (NASDAQ: MASS) and Bio-Techne Corporation (NASDAQ: TECH) today announced a joint collaboration to develop an extended workflow solution for protein characterization. Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and owner of the leading ProteinSimple branded protein analysis portfolio of products
Bio-Techne Announces Commercial Release of Novel DNAscope™ in situ Hybridization Assays for Chromogenic Detection of DNA Copy Number and Structural Variations
Bio-Techne Corporation announced the expansion of the Advanced Cell Diagnostics, a Bio-Techne brand, RNAscope™ technology with release of new DNAscope Assays.
Bio-Techne Corporation announced a license agreement for use of a proprietary Bio-Techne antibody by Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, for its therapeutic development pipeline.
Bio-Techne Announces Commercial Release of Abby Automated Western System for Simple Western and Introduces Stellar Modules for Jess
Abby is the next generation chemiluminescence Western protein analyzer and Stellar modules set the standard for fluorescence sensitivity
Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, May 6, 2021 , at 8:00 a.m. CDT to review third quarter 2021 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: May 6, 2021
Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed the acquisition of Asuragen, Inc. The transaction included initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones.
Bio-Techne Announces Launch of Cultrex UltiMatrix BME to Support Organoid and Pluripotent Stem Cell Cultures
Bio-Techne Corporation (NASDAQ: TECH) today announced the release of Cultrex™ UltiMatrix™ Reduced Growth Factor Basement Membrane Extract (RGF BME), an extracellular matrix hydrogel that provides significant performance and consistency benefits for culturing organoids and pluripotent stem cells.
Bio-Techne Corporation announced that its R&D Systems and Novus brands have been named winners of the CiteAb COVID-19 Innovation Award.
Bio-Techne Corporation announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro diagnostic version of the ExoDx™ Prostate test kit enabling self-certification as CE-IVD as of March 22, 2021.
Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that its Bristol site in the United Kingdom received ISO 9001:2015 Quality Management Systems certification.
Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published preliminary data on its kidney transplant rejection test, ExoTRU™ (Exosome Transplant Rejection Urine), a non-invasive multigene urine-based exosomal mRNA assay.